These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Alternative prostate cancer screening strategies--in response. Gulati R; Etzioni R Ann Intern Med; 2013 May; 158(10):778-9. PubMed ID: 23689774 [No Abstract] [Full Text] [Related]
29. [Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis]. Borkowetz A Urologe A; 2019 Aug; 58(8):925-928. PubMed ID: 31240375 [No Abstract] [Full Text] [Related]
30. General practitioner (GP)'s view on screening for prostate cancer in the Netherlands: the impact of a randomized trial. Schröder FH BJU Int; 2013 Jul; 112(1):4-5. PubMed ID: 23759003 [No Abstract] [Full Text] [Related]
31. Early detection of prostate cancer. Taneja SS Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495 [No Abstract] [Full Text] [Related]
32. Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. Taneja SS J Urol; 2016 Feb; 195(2):350-1. PubMed ID: 26852972 [No Abstract] [Full Text] [Related]
33. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over time. Haines IE Cancer; 2013 Mar; 119(5):1113. PubMed ID: 23097055 [No Abstract] [Full Text] [Related]
34. Laurence Klotz on the Controversy Surrounding Screening for Prostate Cancer. Klotz L Oncology (Williston Park); 2016 Aug; 30(8):694, 764. PubMed ID: 27528237 [No Abstract] [Full Text] [Related]
35. Doing it right: how, not whether, to perform prostate-specific antigen screening. Martin NE Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459 [No Abstract] [Full Text] [Related]
36. Reconsidering Prostate Cancer Screening. Schmidt C J Natl Cancer Inst; 2017 Jan; 109(1):1-2. PubMed ID: 28104781 [No Abstract] [Full Text] [Related]
37. Prostate Cancer Screening: Shared Decision-Making for Screening and Treatment. Blackwelder R; Chessman A Prim Care; 2019 Mar; 46(1):149-155. PubMed ID: 30704655 [TBL] [Abstract][Full Text] [Related]
38. Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over time. Scosyrev E; Messing EM Cancer; 2013 Mar; 119(5):1113-4. PubMed ID: 23097014 [No Abstract] [Full Text] [Related]
39. [Prostate cancer screening: at 40 instead of at 50]. Perspect Infirm; 2014; 11(1):15. PubMed ID: 24551995 [No Abstract] [Full Text] [Related]
40. [Analysis of recommendations against prostate cancer screening with prostate specific antigen]. Abascal Junquera JM; Fumadó Ciutat L; Francés Comalat A; Cecchini Rosell L Med Clin (Barc); 2016 Oct; 147(8):361-365. PubMed ID: 27085747 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]